# Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia

> **NCT00490178** · PHASE3 · COMPLETED · sponsor: **Solvay Pharmaceuticals** · enrollment: 29 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Dyslipidemia

## Interventions

- **DRUG:** Fenofibrate 80 mg and metformin 1000 mg (fixed combination)

## Key facts

- **NCT ID:** NCT00490178
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2007-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00490178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00490178, "Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00490178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*